1) Athan ES, Williamson J., Ciappa A., et al.
A founder mutation in presenilin 1 causing early-onset Alzheimer
disease in unrelated Caribbean Hispanic families.
JAMA 2001; 286: 2257–63 2) Chui H., Zhang Q.
Evaluation of dementia: a systematic study of the usefulness of
the American Academy of Neurology’s practice parameters.
Neurology 1997; 49: 925–35. 3) Cummings J.L., Vinters H.V., Cole G.M., et
al.
Alzheimer’s disease: etiologies, pathophysiology, cognitive
reserve, and treatment opportunities.
Neurology 1998; 51(1 Suppl 1): S2–17; discussion S65–7 4) DeKosky S.T., Orgogozo J.M.
Alzheimer disease: diagnosis, costs, and dimensions of treatment.
Alzheimer Dis Assoc Disord 2001; 15 Suppl 1: S3–7. 5) Dickerson B.C., Goncharova I., Sullivan M.P.,
et al.
MRI-derived entorhinal and hippocampal atrophy in incipient and
very mild Alzheimer’s disease.
Neurobiol Aging 2001; 22: 747–54. 6) Esler W.P., Wolfe M.S.
A portrait of Alzheimer secretases–new features and familiar
faces.
Science 2001; 293: 1449–54 7) Evans D.A., Funkenstein H.H., Albert M.S.,
et al.
Prevalence of Alzheimer’s disease in a community population
of older persons. Higher than previously reported.
JAMA 1989; 262: 2551–6. 8) Geerlings M.I., Schoevers R.A., Beekman A.T.,
et al.
Depression and risk of cognitive decline and Alzheimer’s
disease. Results of 2 prospective community-based studies in The
Netherlands.
Br J Psychiatry. 2000;176:568-575. 9) Grossberg G.T., Desai A.K.
Management of Alzheimer’s disease.
J Gerontol A Biol Sci Med Sci. 2003;58(4):331-353. 10) Hendrie H.C., Ogunniyi A.,
Hall K.S., et al.
Incidence of dementia and Alzheimer disease in 2 communities:
Yoruba residing in Ibadan, Nigeria, and African Americans residing
in Indianapolis, Indiana.
JAMA 2001; 285: 739–47. 11) Katona C.L., Hunter B.N., Bray J.
A double-blind comparison of the efficacy and safety of paroxetine
and imipramine in the treatment of depression with dementia.
Int J Geriatr Psychiatry. 1998;13(2):100-108. 12) Katz I.R., Jeste D.V., Mintzer J.E., Napolitano
J., Brecher M.
Comparison of risperidone and placebo for psychosis and behavioral
disturbances associated with dementia: a randomized, double-blind
trial. Risperidone Study Group.
J Clin Psychiatry. 1999;60(2):107-115. 13) Jeste D.V., Finkel S.I.
Psychosis of Alzheimer’s disease and related dementias.
Diagnostic criteria for a distinct syndrome.
Am J Geriatr Psychiatry. 2000;8(1):29-34. 14) Jhee S., Shiovitz T., Crawford A.W., Cutler
N.R.
Beta-amyloid therapies in Alzheimer’s disease.
Expert Opin Investig Drugs 2001; 10: 593–605. 15) In t’ Veld B.A., Ruitenberg A., Hofman
A., et al.
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s
disease.
N Engl J Med 2001; 345: 1515–21. 16) Maccioni R.B., Munoz J.P., Barbeito L.
The molecular bases of Alzheimer’s disease and other neurodegenerative
disorders.
Arch Med Res 2001; 32: 367–81. 17) LeBlanc E.S., Janowsky J., Chan B.K., Nelson
H.D.
Hormone replacement therapy and cognition: systematic review and
meta-analysis.
JAMA 2001; 285: 1489–99. 18) Liddell M.B., Lovestone S., Owen M.J.
Genetic risk of Alzheimer’s disease: advising relatives.
Br J Psychiatry 2001; 178: 7–11. 19) Lyketsos C.G., Steinberg M., Tschanz J.T.,
Norton M.C., Stevens D.C., Breitner J.C.
Mental and behavioral disturbances in dementia: findings from
the Cache County Study on Memory in Aging.
Am J Psychiatry. 2000;157(5):708-714. 20) Liperoti R., Mor V., Lapane K.L., Pedone
C., Gambassi G., Bernabei R.
The use of atypical antipsychotics in nursing homes.
J Clin Psychiatry. 2003 Sep;64(9):1106-12. 21) Lyketsos C.G., DelCampo L., Steinberg M.,
Miles Q., Steele C.D., Munro C., Baker A.S., Sheppard J.M., Frangakis
C., Brandt J., Rabins P.V.
Treating depression in Alzheimer disease: efficacy and safety
of sertraline therapy, and the benefits of depression reduction:
the DIADS.
Arch Gen Psychiatry. 2003 Jul;60(7):737-46 22) Nyth A.L., Gottfries C.G., Lyby K., et al.
A controlled multicenter clinical study of citalopram and placebo
in elderly depressed patients with and without concomitant dementia.
Acta Psychiatr Scand. 1992;86(2):138-145. 23) O’Brien J.T., Ballard C.G.
Drugs for Alzheimer’s disease.
BMJ 2001; 323: 123–4. 24) O’Connor D.W., Pollitt P.A., Roth M.,
Brook P.B., Reiss B.B.
Memory complaints and impairment in normal, depressed, and demented
elderly persons identified in a community survey.
Arch Gen Psychiatry 1990; 47: 224–7. 25) Olson R.E., Copeland R.A., Seiffert D.
Progress towards testing the amyloid hypothesis: inhibitors of
APP processing.
Curr Opin Drug Discov Devel 2001; 4:390–401. 26) Payne J.L., Sheppard J.M., Steinberg M.,
et al.
Incidence, prevalence, and outcomes of depression in residents
of a long-term care facility with dementia.
Int J Geriatr Psychiatry. 2002;17(3):247-253. 27) Petersen R.C., Stevens J.C., Ganguli M.,
Tangalos E.G., Cummings J.L., DeKosky S.T.
Practice parameter: early detection of dementia: mild cognitive
impairment (an evidence-based review).
Report of the Quality Standards Subcommittee of the American Academy
of Neurology. 2001; 56: 1133–42. 28) Peters R.
The prevention of dementia.
J Cardiovasc Risk 2001; 8: 253–6. 29) Retz W., Thome J., Durany N., et al.
Potential genetic markers of sporadic Alzheimer’s dementia.
Psychiatr Genet 2001; 11: 115–22. 30) Sano M., Ernesto C., Thomas R.G., et al.
A controlled trial of selegiline, alpha-tocopherol, or both as
treatment for Alzheimer’s disease. The Alzheimer’s
Disease Cooperative Study.
N Engl J Med 1997; 336: 1216–22. 31) Satterlee W.S., Reams S.R., Burns P.R., et
al.
A Clinical update on olanzapine treatment in schizophrenia and
in elderly Alzheimer’s disease patients.
Psychopharmacology Bulletin. 1995;31(3):534. 32) Scorer C.A.
Preclinical and clinical challenges in the development of disease-modifying
therapies for Alzheimer’s disease.
Drug Discov Today 2001; 6: 1207–19. 33) Selkoe D.J.
The genetics and molecular pathology of Alzheimer’s disease:
roles of amyloid and the presenilins.
Neurol Clin 2000; 18: 903–22 34) Sloane P.D., Zimmerman S., Suchindran C.,
et al.
The public health impact of Alzheimer’s disease, 2000–2050:
potential implication of treatment advances.
Annu Rev Public Health 2002; 23:213–31. 35) Stern Y., Moeller J.R., Anderson K.E., et
al.
Different brain networks mediate task performance in normal aging
and AD: defining compensation.
Neurology 2000; 55: 1291–7 36) Stewart W.F., Kawas C., Corrada M., Metter
E.J.
Risk of Alzheimer’s disease and duration of NSAID use.
Neurology 1997; 48: 626–32. 37) Street J.S., Clark W.S., Gannon K.S., et
al.
Olanzapine treatment of psychotic and behavioral symptoms in patients
with Alzheimer disease in nursing care facilities: a double-blind,
randomized, placebo-controlled t rial.
The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968-976. 38) Sunderland T., Hill J.L., Mellow A.M., et
al.
Clock drawing in Alzheimer’s disease. A novel measure of
dementia severity.
J Am Geriatr Soc 1989; 37: 725–9. 39) Taragano F.E., Lyketsos C.G., Mangone C.A.,
Allegri R.F., Comesana-Diaz E.
A double-blind, randomized, fixed-dose trial of fluoxetine vs.
amitriptyline in the treatment of major depression complicating
Alzheimer’s disease.
Psychosomatics. 1997;38(3):246-252. 40) Unverzagt F.W., Gao S., Baiyewu O., et al.
Prevalence of cognitive impairment: data from the Indianapolis
Study of Health and Aging.
Neurology 2001; 57: 1655–62. 41) Weisen S.F., Frishman W.H., Aronson M.K.,
Wassertheil-Smoller S.
Self-rated health assessment and development of both cardiovascular
and dementing illnesses in an ambulatory elderly population: a
report from the Bronx Longitudinal Aging Study.
Heart Dis 1999; 1: 201–5 42) Wolf H., Grunwald M., Ecke G.M., et al.
The prognosis of mild cognitive impairment in the elderly.
J Neural Transm Suppl 1998; 54: 31–50. 43) Wooltorton E.
Risperidone (Risperdal): increased rate of cerebrovascular events
in dementia trials.
CMAJ. 2002;167(11):1269-1270.
